News
In COVID-19 patients, risk of bleeding rivals risk of thromboembolism
January 12, 2021
Trials are urgently needed to define optimal anticoagulation strategies for COVID-19 infection.
News
A 4-point thrombocytopenia score was found able to rule out suspected HIT
January 11, 2021
A low score – 3 points or less – has a negative predictive value of 99.8%, “so HIT is basically ruled out.”
News
NETs a possible therapeutic target for COVID-19 thrombosis?
December 31, 2020
Small study, but may provide insight regarding COVID-19 patients who experience acute STEMI.
News
COVID-19 anticoagulation trials ‘paused’ for futility, safety
December 22, 2020
The trials involved are the REMAP-CAP, ACTIV-4, and ATTACC studies.
![1]()
News
A multicenter trial of vena cava filters in severely injured patients
December 9, 2020
Can early (within 72 hours) prophylactic placement of inferior vena cava filter decrease the risk of pulmonary embolism or death in severely injured patients?
![1]()
News
COVID-19 and risk of clotting: ‘Be proactive about prevention’
December 8, 2020
"We believe a systematic way of addressing this risk is best, with every patient hospitalized with COVID-19 receiving some type of thromboprophylaxis," authors of a review article say.
News
Cost is the main hurdle to broad use of caplacizumab for TTP
December 7, 2020
“If we take finances out, I think almost every patient except those with a bleeding risk or bleeding problem should get it,” an investigator said.
News
What to do when anticoagulation fails cancer patients
December 1, 2020
When it comes to “anticoagulation failure, we are entering an evidence free-zone.”
News
Liver injury linked to COVID-19–related coagulopathy
November 18, 2020
Cells that line the liver’s blood vessels produce high levels of factor VIII, a coagulation factor, when they are exposed to interleukin-6, an inflammatory molecule associated with COVID-19.
News
Factor XI inhibitor–based anticoagulation strategies gain ground
November 18, 2020
“When we compare the FXI inhibitors with existing anticoagulants, we don’t necessarily want to go up against the DOACs.”
